

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 14:26:20 ; Search time 0.001 Seconds  
(without alignments)  
521.597 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTRLVTAALLGLMMVV.....PTLQAPRGRASEPKHKTRQR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 11 seqs, 2339 residues

Word size : 0

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 11 summaries

Database : k035rago:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1196	99.3	223	AD134902	Cardiovascular dis
2	1181	98.1	227	AAV94263	Human phospholipid
3	1181	98.1	227	AD588999	Human Phospholipid
4	1181	98.1	227	ADK70502	Respiratory disease
5	1177	97.8	227	AAV35976	Extended human sec
6	1177	97.8	227	AAV64647	Human phosphatidyl
7	1177	97.8	227	AAB88590	Human hydrophobic
8	1173	97.4	227	AD134900	Cardiovascular dis
9	1087	90.3	201	AD134903	Cardiovascular dis
10	1084	88.4	205	AD134901	Cardiovascular dis
11	652	54.2	121	AAV11860	Human 5' EST seque

ALIGNMENTS

RESULT 1  
AD134902  
ID AD134902 standard; protein; 223 AA.  
XX  
AC AD134902;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.  
XX  
KW CPP; CP10; CP11; CAD; cardiovascular disorder plasma polypeptide;  
KW cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;  
XX cardiovascular disorder; coronary artery disease; human.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers

Peptide 1..22 /note= "signal peptide"  
Protein 23..223 /note= "mature protein"  
Disulfide-bond 30..58 /note= "disulphide bridge"  
Disulfide-bond 43..64 /note= "disulphide bridge"  
WO2004005931-A1.  
XX  
XX 15-JAN-2004.  
XX  
XX 26-JUN-2003; 2003WO-EP006766.  
XX  
XX 08-JUL-2002; 2002US-0394576P.  
XX 07-JAN-2003; 2003US-0438664P.  
XX  
XX (GENE-) GENEPROT INC.  
XX  
XX Bougueleret L, Jeandenans C, Pardo B;  
XX  
XX MPI; 2004-108914/11.  
XX SWISSPROT; Q8WW74.  
XX  
XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful  
XX for useful for screening and/or diagnosis of, or predicting  
XX cardiovascular disorder, or for identifying CPP modulator.  
XX  
XX Claim 7; SEQ ID NO 3; 109pp; English.  
XX  
XX Thye invention relates to isolated cardiovascular disorder plasma  
XX polypeptide (CPP), especially CP10 and CP11 and tryptic peptides  
XX derived from them. The CPP fragments are useful for screening and/or  
XX diagnosis of, or predicting a cardiovascular disorder (e.g., coronary  
XX artery disease (CAD)) in a subject. An anti-CPP antibody is useful for  
XX treating cardiovascular disorders e.g., coronary artery disease, stroke,  
XX atherosclerosis, hypertension, etc. The present sequence represents a  
XX human CP11 precursor protein sequence.  
XX  
XX Query Match 99.3%; Score 1196; DB 1; Length 223;  
XX Best Local Similarity 99.1%; Pred. No. 0;  
XX Matches 221; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGWTRLVTAALLGLMMVVTDGDENSPCAEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
DB 1 MGWTRLVTAALLGLMMVVTDGDENSPCAEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
QY 61 VPDCCNTRQKITSWMEPIVKFPGAVDGTATILVMVDPDAPSRAPRPFWRHVLVTDIKG 120  
DB 61 VPDCCNTRQKITSWMEPIVKFPGAVDGTATILVMVDPDAPSRAPRPFWRHVLVTDIKG 120  
QY 121 ADLKKGIQOELSAYQAPSPPAHSGFHRQYFFYLQEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKEGKIQOELSAYQAPSPPAHSGFHRQYFFYLQEGKVISLLPKENKTRGSKWMDRF 180  
QY 181 LNRPHLGEPEASTQFMTQNTQDSPTLQAPRGRASEPKHKTRQR 223  
DB 181 LNRPHLGEPEASTQFMTQNTQDSPTLQAPRGRASEPKHKTRRR 223  
RESULT 2  
AAV94263  
ID AAV94263 standard; protein; 227 AA.  
XX  
AC AAV94263;  
XX  
DT 01-AUG-2000 (first entry)  
XX  
XX Human phospholipid binding protein 2, PLBP2.  
XX

***This Page Blank (uspto)***

Human; phospholipid binding protein; PLBP2; foetal development disorder; reproduction disorder; cell proliferation disorder; immune response; autoimmune disorder; AIDS; infertility; cytostatic; immunosuppressive; gene therapy; hereditary neuropathy; phosphatidylethanolamine binding protein D1; PE-BP D1.

Homo sapiens.

Key Location/Qualifiers  
 Peptide 1..21  
 /label= signal\_peptide  
 Modified-site 4  
 /note= "Thr can be phosphorylated by protein kinase C"  
 Modified-site 21  
 /note= "Thr can be phosphorylated by casein kinase II"  
 Modified-site 67  
 /note= "Tyr can be phosphorylated by tyrosine kinase"  
 Modified-site 73  
 /note= "Ser can be phosphorylated by casein kinase II"  
 Modified-site 101  
 /note= "Ser can be phosphorylated by casein kinase II"  
 Modified-site 169  
 /note= "Aan can be glycosylated"  
 Modified-site 174  
 /note= "Ser can be phosphorylated by protein kinase C"

US6063767-A:

16-MAY-2000.

09-DEC-1998; 98US-00208718.

28-OCT-1997; 97US-00958820.

(INCY-) INCYTE PHARM INC.

Corley NC, Shah P, Lal P, Hillman JL;

WPI; 2000-375529/32.

N-PSDB; AAA15582.

New purified phospholipid binding proteins 1 and 2 useful for diagnosing, treating or preventing diseases disorders associated with fetal development, reproduction, cell proliferation, and the immune response.

Disclosure; Fig 2; 37pp; English.

The present sequence is the phospholipid binding protein 2 (PLBP2). This protein is expressed in lung, prostate and heart tissues. Also, this protein is expressed in foetal tumour tissues. PLBP2 may be used for the diagnosis, prevention, or treatment of disorders associated with foetal development (e.g. hereditary neuropathies), reproduction (e.g. infertility), cell proliferation (e.g. cancers), and the immune response (AIDS). PLBP2 antibodies may also be developed for potential drug screening or to quantitate PLBP2 gene expression in biopsied tissues. The PLBP2 gene may be administered for gene therapy of disorders associated with PLBP2. PLBP2 has high homology with the phosphatidylethanolamine binding protein D1, PE-BP D1, of Onchocerca volvulus. PE-BP D1 is thought to play a role in transport or signal mechanisms between membranes and the cytoplasm

Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

1 MGVTRLVTAALLGLMVMVTTGDENSPCAHEALLDEDTLFCQGLEVPYPLGNIGCKV 60

1 MGVTRLVTAALLGLMVMVTTGDENSPCAHEALLDEDTLFCQGLEVPYPLGNIGCKV 60

61 VPDCCNNYRQKITSMEPIVKFPGVDGATYILVMVDPDAPSAEPRQRFWRHLVTDIKG 120

|||||

Db 61 VPDCCNNYRQKITSMEPIVKFPGVDGATYILVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
 QY 121 ADLKGKIQGELSAYQAPSPAHSGFPHRYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQGELSAYQAPSPAHSGFPHRYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFWMTQNYQDSPTLOAPRGRASEPKHKTR 221  
 Db 181 LNRFLHGEPEASTQFWMTQNYQDSPTLOAPRGRASEPKHKNQ 221

RESULT 3

ADB88999

ID ADB88999 standard; protein; 227 AA.

XX ADB88999;

DT 18-DEC-2003 (first entry)

XX Human Phospholipid binding protein, PLBP2.

XX Phospholipid binding protein; PLBP2; human; membrane biogenesis;

KW foetal development; reproduction; cell proliferation; immune response;

KW Cushing's syndrome; spina bifida; epilepsy; infertility; endometriosis;

KW polycystic ovary syndrome; cancer; leukaemia; lymphoma; AIDS;

KW acquired immunodeficiency syndrome; atherosclerosis; asthma;

KW INCYTE 3126479.

XX Homo sapiens.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 111 /note= "Encoded by AGC"

FT Misc-difference 131 /note= "Encoded by CAC"

FT US2003119730-A1.

PN 26-JUN-2003.

XX 11-JUN-2001; 2001US-00879401.

XX 28-OCT-1997; 97US-00958820.

PR 09-DEC-1998; 98US-00208718.

PR 03-SEP-1999; 99US-00390126.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Hillman JL, Corley NC, Shah P;

XX WPI; 2003-863442/80.

XX N-PSDB; ADB89000.

XX New human phospholipid binding proteins (PLBP) and polynucleotides, useful for diagnosing, preventing or treating diseases or conditions associated with aberrant PLBP expression, e.g. cancer, hepatitis, AIDS or atherosclerosis.

PS Claim 1; Fig 2; 42pp; English.

XX The invention relates to an isolated polypeptide consisting of human phospholipid binding proteins, PLBP1 and PLBP2 (ADB88997 and ADB88999), proteins involved in membrane biogenesis. Also include are their encoding polynucleotides, recombinant polynucleotides, transformed host cells (producing the proteins), an anti-PLBP antibody (or fragment), probes for detecting the polynucleotides, diagnosis/treatment of a PLBP-associated disease, screening for ant/agonists of PLBP and screening for compounds which increase/decrease PLBP expression. The probes are used to detect the polynucleotides. The antibodies are used to detect and purify the polypeptides. The PLBP proteins, polynucleotides, antibodies and isolated compounds are used to diagnose and treat diseases associated with foetal development, reproduction, cell proliferation and the immune response, e.g. Cushing's syndrome, spina bifida, epilepsy, infertility,

**This Page Blank (uspto)**

CC endometriosis, polycystic ovary syndrome, cancer, leukaemia, lymphoma,  
 CC AIDS (acquired immunodeficiency syndrome), atherosclerosis and asthma  
 CC (many more examples of these diseases are shown in the specification).  
 CC The present sequence represents human PLEP1.

XX SQ Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Qy 61 VPCNNYRQKITSWMEPIVKPGAVDGYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKPGAVDGYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Qy 121 ADLKGKIQGOELSAVQAPSPPAHSGFPHRYOFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQGOELSAVQAPSPPAHSGFPHRYOFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Qy 181 LNRHFLGPEASTQPMYQDSPTLQAPRGRASEPKHKTR 221  
 Db 181 LNRHFLGPEASTQPMYQDSPTLQAPRGRASEPKHKQ 221

#### RESULT 4

ADK70502  
 ID ADK70502 standard; protein; 227 AA.

XX AC ADK70502;

XX DT 06-MAY-2004 (first entry)

XX DE Respiratory disease differentially expressed protein #68.

XX KW cytostatic; respiratory; antiasthmatic; gene therapy;

XX KW differential gene expression; respiratory disorder; lung cancer;

XX KW chronic obstructive pulmonary disease; emphysema; asthma.

XX OS Homo sapiens.

XX PN WO2003101283-A2.

XX PD 11-DEC-2003.

XX PF 02-JUN-2003; 2003WO-US017409.

XX PR 04-JUN-2002; 2002US-0386005P.

XX PA (INCY-) INCYTE CORP.

XX PI Rickert PK, Krasnow R;

XX PS WPI; 2004-042945/04.

XX PT New combination comprising cDNAs and proteins that are differentially  
 expressed in respiratory disorders, useful for diagnosing or treating  
 respiratory diseases e.g. lung cancer, chronic obstructive pulmonary  
 diseases or asthma.

XX PS Claim 14; SEQ ID NO 238; 343pp; English.

XX CC The invention relates to cDNA sequences that are differentially expressed  
 in respiratory disorders or their complements or encoded proteins. The  
 cDNAs and proteins are useful for diagnosing, treating or monitoring  
 treatment of a subject with a respiratory disease including lung cancer,  
 chronic obstructive pulmonary diseases, emphysema or asthma. The protein  
 is also useful for screening molecules or compounds to identify at least  
 one ligand which specifically binds the protein. It is also useful for  
 preparing and purifying a polyclonal or monoclonal antibody. This

CC sequence corresponds to a protein of the invention.

XX SQ Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Qy 61 VPCNNYRQKITSWMEPIVKPGAVDGYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKPGAVDGYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Qy 121 ADLKGKIQGOELSAVQAPSPPAHSGFPHRYOFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQGOELSAVQAPSPPAHSGFPHRYOFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Qy 181 LNRHFLGPEASTQPMYQDSPTLQAPRGRASEPKHKTR 221  
 Db 181 LNRHFLGPEASTQPMYQDSPTLQAPRGRASEPKHKQ 221

#### RESULT 5

AAV35976

ID AAV35976 standard; protein; 227 AA.

XX AC AAV35976;

XX DT 13-SEP-1999 (first entry)

XX DE Extended human secreted protein sequence, SEQ ID NO. 225.

XX KW Secreted protein; human; cytokine; cellular proliferation; cell movement;  
 cellular differentiation; immune system regulator; anti-inflammatory;  
 haematopoiesis regulator; tissue growth regulator; tumour inhibitor;  
 reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;  
 genetic disease.

XX OS Homo sapiens.

XX PN WO9911236-A2.

XX PD 24-JUN-1999.

XX PF 17-DEC-1998; 98WO-18002122.

XX PR 17-DEC-1997; 97US-0069957P.

XX PR 09-FEB-1998; 98US-0074121P.

XX PR 13-APR-1998; 98US-0081563P.

XX PR 10-AUG-1998; 98US-0096116P.

XX PA (GEST ) GENSET.

XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;

XX DR WPI; 1999-385906/32.

XX DR N-PSDB; AAX97660.

XX PT New isolated human secreted proteins.

XX PS Claim 9; Page 255; 516pp; English.

XX CC This sequence is encoded by an extended human secreted protein coding  
 sequence of the invention. The secreted proteins can be used in treating  
 or controlling a variety of human conditions. The secreted proteins may  
 act as cytokines or may affect cellular proliferation or differentiation  
 or may act as immune system regulators, haematopoiesis regulators, tissue  
 growth regulators, regulators of reproductive hormones or cell movement  
 or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or  
 tumour inhibition activity. The DNAs can be used in forensic procedures

This Page Blank (uspto)

CC to identify individuals or in diagnostic procedures to identify  
 CC individuals having genetic diseases resulting from abnormal expression of  
 CC the genes corresponding to the extended cDNAs. They are also useful for  
 CC constructing a high resolution map of the human chromosomes. They can  
 CC also be used for gene therapy to control or treat genetic diseases  
 XX  
 SQ Sequence 227 AA;

Query Match 97.8%; Score 1177; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MGWTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 DB 1 MGWTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPRAEPQRFWRHLVTDIKG 120  
 DB 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPRAEPQRFWRHLVTDIKG 120  
 QY 121 ADLKGKIQOELSAQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQOELSAQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTONTQYQDSPTLQAPRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFTONTQYQDSPTLQAPRASEPKHKTR 221

RESULT 6  
 AAY64647  
 ID AAY64647 standard; protein; 227 AA.  
 XX  
 AC AAY64647;  
 XX  
 DT 01-FEB-2000 (first entry)  
 XX  
 DE Human phosphatidylethanolamine-binding protein.  
 XX  
 KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
 KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
 KW location; development; protein synthesis; stability; regulation;  
 KW identification.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO9553051-A2.  
 XX  
 PD 21-OCT-1999.  
 XX  
 PF 09-APR-1999; 99WO-IB000712.  
 XX  
 PR 09-APR-1998; 98US-00057719.  
 PR 28-APR-1998; 98US-00069047.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 XX Dumas Milne Edwards, Duclert A, Giordano J;  
 XX WPI; 2000-038446/03.  
 XX DR N-PSDB; AA242252.  
 XX

Novel secreted protein 5' expressed sequence tag sequences used in  
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.  
 PT  
 XX Example 21; Page 169-170; 837pp; English.  
 XX  
 CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)  
 CC sequences, corresponding to human secreted proteins. AA242265 to AA243075  
 CC represent the EST-related proteins corresponding to AA242265 to AA243052.  
 CC The 5' ESTs can be used for producing secreted human gene products. They  
 CC can be used to identify and isolate 5' untranslated regions (UTRs) and  
 CC upstream regulatory regions which control the location, development

CC stage, rate, and quantity of protein synthesis, as well as stability of  
 CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to  
 CC obtain full length cDNA clones. The ESTs can also be used in forensic  
 CC procedures to identify individuals, or in diagnostic procedures to  
 CC identify individuals having genetic diseases resulting from abnormal gene  
 CC expression. The products may also be used in gene therapy protocols. The  
 CC nucleic acids encoding signal peptides can be used for directing  
 CC extracellular secretion of a polypeptide or the insertion of a  
 CC polypeptide into a membrane, or importing a polypeptide into a cell. The  
 CC proteins encoded by the EST sequences may be useful in treating a variety  
 CC of human conditions. Secreted proteins have therapeutic value, and the  
 CC identification of new secreted proteins is valuable. AA242249 to AA242264  
 CC and AA242265 to AA242266 represent sequences used in the exemplification  
 CC of the present invention  
 XX  
 SQ Sequence 227 AA;

Query Match 97.8%; Score 1177; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MGWTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 DB 1 MGWTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPRAEPQRFWRHLVTDIKG 120  
 DB 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPRAEPQRFWRHLVTDIKG 120  
 QY 121 ADLKGKIQOELSAQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQOELSAQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTONTQYQDSPTLQAPRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFTONTQYQDSPTLQAPRASEPKHKTR 221

RESULT 7  
 AAB88590  
 ID AAB88590 standard; protein; 227 AA.  
 XX  
 AC AAB88590;  
 XX  
 DT 04-JUN-2001 (first entry)  
 XX  
 DE Human hydrophobic domain containing protein clone HP03880 #94.  
 XX  
 KW Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;  
 KW antianemic; vulnery; antitumor; osteopathic; anti-inflammatory;  
 KW cytosolic; gene therapy; autoimmune disorder; multiple sclerosis;  
 KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;  
 KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;  
 KW behavioural characteristic; immune response.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200112660-A2.  
 XX  
 PD 22-FEB-2001.  
 XX  
 PF 10-AUG-2000; 2000WO-JP005356.  
 XX  
 PR 17-AUG-1999; 99JP-00230344.  
 PR 07-SEP-1999; 99JP-00252551.  
 PR 01-OCT-1999; 99JP-00281132.  
 PR 22-OCT-1999; 99JP-00301624.  
 PR 04-NOV-1999; 99JP-00313877.  
 XX  
 PA (SAGA ) SAGAMI CHEM RES CENT.  
 PA (PROT-) PROTEGENE INC.  
 XX  
 PI Kato S, Kimura T;

This Page Blank (uspto)



OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-895-298-107

Query Match 97.3%; Score 1171; DB 1; Length 227;  
Best Local Similarity 98.2%; Pred. No. 0;  
Matches 217; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 MGWTNRLVTAALLLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGWTNRLVTAALLLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60

QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSRAPRQRFWRHLVTDIKG 120  
DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSRAPRQRFWRHLVTDIKG 120

QY 121 ADLKKGKIQQGELSAYQAPSPPAHSGFHRYPFFVYLQEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKKGKIQQGELSAYQAPSPPAHSGFHRYPFFVYLQEGKVISLLPKENKTRGSKWMDRF 180

QY 181 LNRPHLGEPEASTQPMTONYQDSPTLQAPRASEPKHKTR 221  
DB 181 LNRPHLGEPEASTQPMTONYQDSPTLQAPRASEPKHKTR 221

Search completed: February 22, 2005, 14:27:55  
Job time : 1 secs

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 22, 2005, 14:27:54 ; Search time 1 Seconds  
(without alignments)  
0.051 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTNRLVTAALLLGLMMVV.....PTLQAPRGRASEPKHKTRQ 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 227 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 1 summaries

Database : k035rapbo:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				
Result No.	Score	Query Match	Length DB ID	Description
1	1171	97.3	227 1	US-09-895-298-107 Sequence 107, App

ALIGNMENTS

RESULT 1  
US-09-895-298-107  
; Sequence 107, Application US/09895298  
; Publication No. US20030078405A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 47 Human Secreted Proteins  
; FILE REFERENCE: P2035P1  
; CURRENT APPLICATION NUMBER: US/09/895,298  
; PRIOR FILING DATE: 2001-07-02  
; PRIOR APPLICATION NUMBER: 09/591,16  
; PRIOR FILING DATE: 2000-06-09  
; PRIOR APPLICATION NUMBER: PCT/US99/29950  
; PRIOR FILING DATE: 1999-12-16  
; PRIOR APPLICATION NUMBER: 60/113,006  
; PRIOR FILING DATE: 1998-12-18  
; PRIOR APPLICATION NUMBER: 60/112,809  
; PRIOR FILING DATE: 1998-12-17  
; NUMBER OF SEQ ID NOS: 231  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 107  
; LENGTH: 227  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (125)

...is Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 12:59:09 ; Search time 0.001 Seconds  
(without alignments)  
101.242 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTMLVTAALLGLMMVV.....PTLQAPGRASEPKHKTRQR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2 seqs, 454 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 2 summaries

Database : k035rapb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1181	98.1	227	1 US-09-879-401-3	Sequence 3, Appli
2	1173	97.4	227	1 US-10-003-152-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1

US-09-879-401-3  
; Sequence 3, Application US/09879401  
; Publication No. US20030119730A1  
; GENERAL INFORMATION:  
; APPLICANT: Lal, Preeti  
; Hillman, Jennifer  
; Corley, Neil  
; Shah, Purvi  
; TITLE OF INVENTION: HUMAN PHOSPHOLIPID BINDING PROTEINS  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: Incyte Pharmaceuticals, Inc.  
; STREET: 3174 Porter Dr.  
; CITY: Palo Alto  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/879,401  
; FILING DATE: 11-Jun-2001

CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/958,820  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Billings, Lucy J.  
; REGISTRATION NUMBER: 36,749  
; REFERENCE/DOCKET NUMBER: PF-0379 US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-855-0555  
; TELEFAX: 650-845-4166  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 227 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; LIBRARY: LUNGUTUT12  
; CLONE: 3126479  
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
US-09-879-401-3

Query Match 98.1%; Score 1181; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MGWTMLVTAALLGLMMVVTDGDENSPCAHEALLDSDTLFCQGLEVFYPELGNIGCKV 60  
DB 1 MGWTMLVTAALLGLMMVVTDGDENSPCAHEALLDSDTLFCQGLEVFYPELGNIGCKV 60  
QY 61 VPDCCNYRQKITSWMEPIVKFPGAVDGYTYLLVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
DB 61 VPDCCNYRQKITSWMEPIVKFPGAVDGYTYLLVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
QY 121 ADLKKGIQGOELSAQAPSPAHSGFHYOFFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKEGKIQGOELSAQAPSPAHSGFHYOFFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
QY 181 LNRHFLGPEASTQPMTONYQDSPTLQAPGRASEPKHKTR 221  
DB 181 LNRHFLGPEASTQPMTONYQDSPTLQAPGRASEPKHKQ 221

RESULT 2

US-10-003-152-2  
; Sequence 2, Application US/10003152  
; Publication No. US20020151494A1  
; GENERAL INFORMATION:  
; APPLICANT: Shimkets, Richard  
; APPLICANT: Fernandes, Elma  
; APPLICANT: Vernet, Corine  
; APPLICANT: Yang, Meijia  
; APPLICANT: Boldog, Ferenc  
; APPLICANT: Herrmann, John  
; TITLE OF INVENTION: No. US20020151494A1el Amino Acid Sequences for Human Semaphorin-1  
; FILE REFERENCE: 15966-554 Cura-54 CON-S12  
; CURRENT APPLICATION NUMBER: US/10/003,152  
; CURRENT FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 09/604,286  
; PRIOR FILING DATE: 2000-06-22  
; PRIOR APPLICATION NUMBER: 60/140,584  
; PRIOR FILING DATE: 1999-06-23  
; NUMBER OF SEQ ID NOS: 49  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 227  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-003-152-2  
Query Match 97.4%; Score 1173; DB 1; Length 227;  
Best Local Similarity 98.2%; Pred. No. 0;

Matches 217;		Conservative	2;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1	MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV	60						
Db	1	MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV	60						
Qy	61	VPDCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSRABPRQRFWRHNLVTDIKG	120						
Db	61	VPDCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSRABPRQRFWRHNLVTDIKG	120						
Qy	121	ADLKGKIQGQELSAQAPSPAHSGFHRHQFFVYLOEGKVISLLPKENKTRGSKMDRF	180						
Db	121	ADLKGKIQGQELSAQAPSPAHSGFHRHQFFVYLOEGKVISLLPKENKTRGSKMDRF	180						
Qy	181	LNRFLGPEPEASTQFMNTQNYQDSPTLOAPRASEPKHKTR	221						
Db	181	LNRFLGPEPEASTQFMNTQNYQDSPTLOAPRASEPKHKNQ	221						

Search completed: February 22, 2005, 12:59:09  
Job time : 0.001 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 12:54:10 ; Search time 0.001 Seconds  
(without alignments)  
612.135 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGMTWRLVTAALLGLMMVV.....PTLQAPRGRASEPKHKTROR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 13 seqs, 2745 residues

Total number of hits satisfying chosen parameters: 13

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 13 summaries

Database : k035rag:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1200	99.7	223	1 AAU14138	Human novel protei
2	1196	99.3	223	1 ADI34902	Cardiovascular dis
3	1181	98.1	227	1 AAY94263	Human phospholipid
4	1181	98.1	227	1 AD888999	Human Phospholipid
5	1181	98.1	227	1 ADK70502	Respiratory disease
6	1177	97.8	227	1 AAY35976	Extended human sec
7	1177	97.8	227	1 AAY64647	Human phosphatidyl
8	1177	97.8	227	1 AAB88590	Human hydrophobic
9	1173	97.4	227	1 ADI34900	Cardiovascular dis
10	1087	90.3	201	1 ADI34903	Cardiovascular dis
11	1064	88.4	205	1 ADI34901	Cardiovascular dis
12	743.5	61.8	183	1 ADH80692	Human polypeptide
13	652	54.2	121	1 AAY11860	Human 5' EST seque

ALIGNMENTS

RESULT 1  
AAU14138  
ID AAU14138 standard; protein; 223 AA.  
XX  
AC AAU14138;  
XX  
DT 24-OCT-2001 (first entry)  
XX  
XX Human novel protein #9.  
DE  
XX  
KW Human; novel protein; Antianaemic; osteopathic; antiinflammatory;  
KW immunomodulatory; cytoskeletal; neuroprotective; vulnary; nootropic;  
KW anticonvulsant; antiarthritic; cerebroprotective; antifungal; antiviral;  
KW antibacterial; antiallergic; dermatological; haemostatic; antiasthmatic;  
KW thrombolytic; immunogen; antibody; gene therapy; neurological disorder;

KW Parkinson's disease; inflammatory disorder; cancer; asthma; osteoporosis;  
XX tissue regeneration; immune disorder.  
OS Homo sapiens.  
XX WO200155437-A2.  
XX  
PD 02-AUG-2001.  
XX  
XX 25-JAN-2001; 2001WO-US002623.  
XX  
XX 25-JAN-2000; 2000US-00491404.  
XX  
XX (HYSE-) HYSEQ INC.  
XX  
XX Tang YT, Liu C, Drmanac RT;  
XX WPI; 2001-451939/48.  
XX DR N-PSDB; AAS22443.  
XX  
XX Isolated polypeptides useful for treating anti-inflammatory diseases,  
PT nervous system disorders, and for regenerating bone and cartilage.  
XX  
XX Example 4; Page 528-529; 894pp; English.  
XX  
XX The invention relates to polynucleotides encoding novel human proteins or  
CC their active domains. The polypeptides, polynucleotides and antibodies  
CC raised against the polypeptides are used in a method of treatment of a  
CC mammal and prevention of disorders caused by the aberrant protein  
CC expression or activity. The polypeptides can be used as molecular weight  
CC markers, food supplements, and in antibody production. The polypeptides  
CC are used to identify compounds which bind to the polypeptides.  
CC Polynucleotides of the invention are used as probes and primers, for  
CC sequencing, for chromosome or gene mapping, in the production of  
CC recombinant proteins, and in generating anti-sense DNA or RNA and in gene  
CC therapy. Polypeptides of the invention can be used to target drugs to a  
CC tumour, in assays to determine biological activity, to raise  
CC antibodies/elicit an immune response, to determine quantitative protein  
CC levels, as tissue markers, and to isolate receptors or ligands.  
CC Polypeptides of the invention may also be useful in treating platelet  
CC disorders, stem cell disorders, regenerating bone, cartilage, tendon,  
CC ligament and/or nerve tissue, wound healing, treating burns, promoting  
CC the proliferation, differentiation and survival of stem cells, as a  
CC contraceptive, treating osteoporosis and osteoarthritis, anaemia,  
CC Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral  
CC sclerosis, stroke, immune deficiencies resulting from bacterial, viral or  
CC fungal infection or from autoimmunity, cancer, allergy, asthma, graft-  
CC versus-host disease, eczema, haemophilia, thrombosis, anti-inflammatory  
CC diseases, nervous system disorders, and infection. The present sequence  
CC represents a protein of the invention  
SQ Sequence 223 AA;

Query Match 99.7%; Score 1200; DB 1; Length 223;  
Best Local Similarity 99.6%; Pred. No. 0;  
Matches 222; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGMTWRLVTAALLGLMMVVTTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
DB 1 MGMTWRLVTAALLGLMMVVTTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
QY 61 VPDCCNNYRQKITSWMEPIVKFPFGAVDGYATILVMVDPDAPSAEPQRQFRHVLVTDIKG 120  
DB 61 VPDCCNNYRQKITSWMEPIVKFPFGAVDGYATILVMVDPDAPSAEPQRQFRHVLVTDIKG 120  
QY 121 ADLKKGKTGGELSAQAPSPAHSGFHYOFFVYVLOEGKVTLSPKENKTRGSKWMDRF 180  
DB 121 ADLKEGKTGGELSAQAPSPAHSGFHYOFFVYVLOEGKVTLSPKENKTRGSKWMDRF 180  
QY 181 LNRPHLGEPEASTQMTQNYQDSPTLQAPRGRASEPKHKTROR 223  
DB 181 LNRPHLGEPEASTQMTQNYQDSPTLQAPRGRASEPKHKTROR 223

```

RESULT 2
ADI34902
ID ADI34902 standard; protein; 223 AA.
XX AC ADI34902;
XX DT 06-MAY-2004 (first entry)
XX DE Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.
XX KW CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
KW cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
KW cardiovascular disorder; coronary artery disease; human.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Peptide 1..22
XX FT Protein /note="signal peptide"
XX FT Disulfide-bond 23..223
XX FT Disulfide-bond /note="mature protein"
XX FT Disulfide-bond 30..58
XX FT Disulfide-bond /note = disulphide bridge
XX FT Disulfide-bond 43..64
XX FT /note = disulphide bridge
XX WO2004005931-A1.
XX 15-JAN-2004.
XX 26-JUN-2003; 2003WO-EP006766.
XX 08-JUL-2002; 2002US-0394576P.
XX 07-JAN-2003; 2003US-0438664P.
XX (GENE-) GENEPROT INC.
XX Bougueleret L, Jeandenans C, Pardo B;
XX WPI: 2004-108914/11.
XX SWISSPROT; Q8WV74.
XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
XX for useful for screening and/or diagnosis of, or predicting
XX cardiovascular disorder, or for identifying CPP modulator.
XX Claim 7; SEQ ID NO 3; 109pp; English.
XX Thye invention relates to isolated cardiovascular disorder plasma
XX polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
XX derived from them. The CPP fragments are useful for screening and/or
XX diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
XX artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
XX treating cardiovascular disorders e.g., coronary artery disease, stroke,
XX atherosclerosis, hypertension, etc. The present sequence represents a
XX human CPP11 precursor protein sequence.
XX SQ Sequence 223 AA;
Query Match 99.3%; Score 1196; DB 1; Length 223;
Best Local Similarity 99.1%; Pred. No. 0;
Matches 221; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGMTWRLVTAALLGLMMVVTGDEBNSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGMTWRLVTAALLGLMMVVTGDEBNSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
QY 61 VPDCCNNYRKITSWMEPIVKFFGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
DB 61 VPDCCNNYRKITSWMEPIVKFFGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
QY 121 ADLKGKIQGQELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSWKMDRF 180

```

---

```

Db 121 ADLKGKIQGQELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSWKMDRF 180
QY 181 LNRFHLGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTROR 223
DB 181 LNRFHLGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTRRR 223

RESULT 3
AAY94263
ID AAY94263 standard; protein; 227 AA.
XX AC AAY94263;
XX DT 01-AUG-2000 (first entry)
XX DE Human phospholipid binding protein 2, PLBP2.
XX KW Human; phospholipid binding protein; PLBP2; foetal development disorder;
KW reproduction disorder; cell proliferation disorder; immune response;
KW autoimmune disorder; AIDS; infertility; cytostatic; immunosuppressive;
KW gene therapy; hereditary neuropathy;
KW phosphatidylethanolamine binding protein D1; PE-BP D1.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Peptide 1..21
XX FT Modified-site 4
XX FT Modified-site /label= signal_peptide
XX FT Modified-site /note= "Thr can be phosphorylated by protein kinase C"
XX FT Modified-site 21
XX FT Modified-site /note= "Thr can be phosphorylated by casein kinase II"
XX FT Modified-site 67
XX FT Modified-site /note= "Tyr can be phosphorylated by tyrosine kinase"
XX FT Modified-site 73
XX FT Modified-site /note= "Ser can be phosphorylated by casein kinase II"
XX FT Modified-site 101
XX FT Modified-site /note= "Ser can be phosphorylated by casein kinase II"
XX FT Modified-site 169
XX FT Modified-site /note= "Asn can be glycosylated"
XX FT Modified-site 174
XX FT Modified-site /note= "Ser can be phosphorylated by protein kinase C"
XX US6063767-A.
XX 16-MAY-2000.
XX 09-DEC-1998; 98US-00208718.
XX 28-OCT-1997; 97US-00958820.
XX (INCY-) INCYTE PHARM INC.
XX Corley NC, Shah P, Lal P, Hillman JL;
XX WPI: 2000-375529/32.
XX N-PSDB; AAA15582.
XX New purified phospholipid binding proteins 1 and 2 useful for diagnosing,
XX treating or preventing diseases disorders associated with fetal
XX development, reproduction, cell proliferation, and the immune response.
XX Disclosure; Fig 2; 37pp; English.
XX The present sequence is the phospholipid binding protein 2 (PLBP2). This
XX protein is expressed in lung, prostate and heart tissues. Also, this
XX protein is expressed in foetal tumour tissues. PLBP2 may be used for the
XX diagnosis, prevention, or treatment of disorders associated with foetal
XX development (e.g. hereditary neuropathies), reproduction (e.g.
XX infertility), cell proliferation (e.g. cancers), and the immune response
XX (AIDS). PLBP2 antibodies may also be developed for potential drug
XX screening or to quantitate PLBP2 gene expression in biopsied tissues. The

```

CC PLBP2 gene may be administered for gene therapy of disorders associated  
 CC with PLBP2. PLBP2 has high homology with the phosphatidylethanolamine  
 CC binding protein DI, PE-BP DI, of *Onchocerca volvulus*. PE-BP DI is thought  
 CC to play a role in transport or signal mechanisms between membranes and  
 CC the cytoplasm

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYVPELGNIGCKV 60  
 DB 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYVPELGNIGCKV 60  
 QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120  
 DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKNQ 221

#### RESULT 4

ADB88999  
 ID ADB88999 standard; protein; 227 AA.

XX ADB88999;

DT 18-DEC-2003 (first entry)

XX Human Phospholipid binding protein, PLBP2.

XX Phospholipid binding protein; PLBP2; human; membrane biogenesis;  
 KW foetal development; reproduction; cell proliferation; immune response;  
 KW Cushing's syndrome; spina bifida; epilepsy; infertility; endometriosis;  
 KW polycystic ovary syndrome; cancer; leukaemia; lymphoma; AIDS;  
 KW acquired immunodeficiency syndrome; atherosclerosis; asthma;  
 KW INCYTE 3126479.

XX Homo sapiens.

OS Key Location/Qualifiers

FT Misc-difference 111 /note= "Encoded by AGC"

FT Misc-difference 131 /note= "Encoded by CAC"

XX US2003119730-A1.

XX 26-JUN-2003.

XX 11-JUN-2001; 2001US-00879401.

XX 28-OCT-1997; 97US-00958820.

XX 09-DEC-1998; 98US-00208718.

XX 03-SEP-1999; 99US-00390126.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Hillman JL, Corley NC, Shah P;

XX WPI; 2003-863442/80.

XX N-PSDB; ADB89000.

XX New human phospholipid binding proteins (PLBP) and polynucleotides,

XX useful for diagnosing, preventing or treating diseases or conditions

PT associated with aberrant PLBP expression, e.g. cancer, hepatitis, AIDS or  
 PT atherosclerosis.

XX Claim 1; Fig 2; 42pp; English.

XX The invention relates to an isolated polypeptide consisting of human  
 CC phospholipid binding proteins, PLBP1 and PLBP2 (ADB88997 and ADB88999),  
 CC proteins involved in membrane biogenesis. Also include are their encoding  
 CC polynucleotides, recombinant polynucleotides, transformed host cells  
 CC (producing the proteins), an anti-PLBP antibody (or fragment), probes for  
 CC detecting the polynucleotides, diagnosis/treatment of a PLBP-associated  
 CC disease, screening for ant/agonists of PLBP and screening for compounds  
 CC which increase/decrease PLBP expression. The probes are used to detect  
 CC the polynucleotides. The antibodies are used to detect and purify the  
 CC polypeptides. The PLBP proteins, polynucleotides, antibodies and isolated  
 CC compounds are used to diagnose and treat diseases associated with foetal  
 CC development, reproduction, cell proliferation and the immune response,  
 CC e.g. Cushing's syndrome, spina bifida, epilepsy, infertility,  
 CC endometriosis, polycystic ovary syndrome, cancer, leukaemia, lymphoma,  
 CC AIDS (acquired immunodeficiency syndrome), atherosclerosis and asthma,  
 CC (many more examples of these diseases are shown in the specification).  
 CC The present sequence represents human PLBP1.

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYVPELGNIGCKV 60  
 DB 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYVPELGNIGCKV 60  
 QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120  
 DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKNQ 221

#### RESULT 5

ADK70502

ID ADK70502 standard; protein; 227 AA.

XX ADK70502;

XX 06-MAY-2004 (first entry)

XX Respiratory disease differentially expressed protein #68.

XX cytostatic; respiratory; antiasthmatic; gene therapy;  
 KW differential gene expression; respiratory disorder; lung cancer;  
 KW chronic obstructive pulmonary disease; emphysema; asthma.

XX Homo sapiens.

XX WO2003101283-A2.

XX 11-DEC-2003.

XX 02-JUN-2003; 2003WO-US017409.

XX 04-JUN-2002; 2002US-0386005P.

XX (INCY-) INCYTE CORP.

XX Rickert PK, Kraenow R;

```

XX WPI; 2004-042945/04.
XX
XX New combination comprising cDNAs and proteins that are differentially
PT expressed in respiratory disorders, useful for diagnosing or treating
PT respiratory diseases e.g. lung cancer, chronic obstructive pulmonary
PT diseases or asthma.
XX
XX Claim 14; SEQ ID NO 238; 343pp; English.
XX
XX The invention relates to cDNA sequences that are differentially expressed
CC in respiratory disorders or their complements or encoded proteins. The
CC cDNAs and proteins are useful for diagnosing, treating or monitoring
CC treatment of a subject with a respiratory disease including lung cancer,
CC chronic obstructive pulmonary diseases, emphysema or asthma. The protein
CC is also useful for screening molecules or compounds to identify at least
CC one ligand which specifically binds the protein. It is also useful for
CC preparing and purifying a polyclonal or monoclonal antibody. This
CC sequence corresponds to a protein of the invention.
XX
XX Sequence 227 AA;
SQ
Query Match 98.1%; Score 1181; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1 MGWTWRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGWTWRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
QY 61 VPDCCNRYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSAEPQRFWRHVLVTDIKG 120
DB 61 VPDCCNRYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSAEPQRFWRHVLVTDIKG 120
QY 121 ADLKGKIQOGLSAYQAPSPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQOGLSAYQAPSPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRGRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRGRASEPKHKTR 221
RESULT 6
AAV35976
ID AAY35976 standard; protein; 227 AA.
XX
XX AAY35976;
AC
XX
XX 13-SEP-1999 (first entry)
DT
XX
XX Extended human secreted protein sequence, SEQ ID NO. 225.
DE
XX Secreted protein; human; cytokine; cellular proliferation; cell movement;
XX cellular differentiation; immune system regulator; anti-inflammatory;
XX haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
XX reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
XX genetic disease.
XX
XX Homo sapiens.
OS
XX
XX WO9931236-A2.
PN
XX
XX 24-JUN-1999.
PD
XX
XX 17-DEC-1998; 98WO-IB002122.
PF
XX
XX 17-DEC-1997; 97US-0069957P.
PR
XX
XX 09-FEB-1998; 98US-0074121P.
PR
XX
XX 13-APR-1998; 98US-0081563P.
PR
XX
XX 10-AUG-1998; 98US-0096116P.
PR
XX
XX (GIST ) GENSET.
PA

```

```

XX Bougueleret L, Duclert A, Dumas Milne Edwards J;
PI
XX WPI; 1999-385906/32.
DR
XX N-FSD; AAX97660.
DR
XX New isolated human secreted proteins.
PT
XX
XX Claim 9; Page 255; 516pp; English.
PS
XX
XX This sequence is encoded by an extended human secreted protein coding
CC sequence of the invention. The secreted proteins can be used in treating
CC or controlling a variety of human conditions. The secreted proteins may
CC act as cytokines or may affect cellular proliferation or differentiation
CC or may act as immune system regulators, haematopoiesis regulators, tissue
CC growth regulators, regulators of reproductive hormones or cell movement
CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
CC tumour inhibition activity. The DNAs can be used in forensic procedures
CC to identify individuals or in diagnostic procedures from abnormal expression of
CC individuals having genetic diseases resulting from abnormal expression of
CC the genes corresponding to the extended cDNAs. They are also useful for
CC constructing a high resolution map of the human chromosomes. They can
CC also be used for gene therapy to control or treat genetic diseases
XX
XX Sequence 227 AA;
SQ
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTWRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGWTWRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
QY 61 VPDCCNRYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSAEPQRFWRHVLVTDIKG 120
DB 61 VPDCCNRYRQKITSWMEPIVKFPGAVDGYATYILVMVDPDAPSAEPQRFWRHVLVTDIKG 120
QY 121 ADLKGKIQOGLSAYQAPSPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQOGLSAYQAPSPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRGRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRGRASEPKHKTR 221
RESULT 7
AAV64647
ID AAY64647 standard; protein; 227 AA.
XX
XX AAY64647;
AC
XX
XX 01-FEB-2000 (first entry)
DT
XX
XX Human phosphatidylethanolamine-binding protein.
DE
XX
XX Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
XX gene therapy; chromosome mapping; upstream regulatory sequence; forensic;
XX location; development; protein synthesis; stability; regulation;
XX identification.
XX
XX Homo sapiens.
OS
XX
XX WO9953051-A2.
PN
XX
XX 21-OCT-1999.
PD
XX
XX 09-APR-1999; 99WO-IB000712.
PF
XX
XX 09-APR-1998; 98US-00057719.
PR
XX
XX 28-APR-1998; 98US-00069047.
PR
XX

```



```

PA (GEST ) GENSET.
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX WPI; 2000-038446/03.
XX DR N-PSDB; AA242252.
XX
PT Novel secreted protein 5' expressed sequence tag sequences used in
PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.
XX
XX Example 21; Page 169-170; 837pp; English.
XX
CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)
CC sequences, corresponding to human secreted proteins. AA242265 to AA242265
CC represent the EST-related proteins corresponding to AA242265 to AA243052.
CC The 5' ESTs can be used for producing secreted human gene products. They
CC can be used to identify and isolate 5' untranslated regions (UTRs) and
CC upstream regulatory regions which control the location, development
CC stage, rate, and quantity of protein synthesis, as well as stability of
CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to
CC obtain full length cDNA clones. The ESTs can also be used in forensic
CC procedures to identify individuals, or in diagnostic procedures to
CC identify individuals having genetic diseases resulting from abnormal gene
CC expression. The products may also be used in gene therapy protocols. The
CC nucleic acids encoding signal peptides can be used for directing
CC extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell. The
CC proteins encoded by the EST sequences may be useful in treating a variety
CC of human conditions. Secreted proteins have therapeutic value, and the
CC identification of new secreted proteins is valuable. AA242249 to AA242264
CC and AA242264 to AA242265 represent sequences used in the exemplification
CC of the present invention
XX
SQ Sequence 227 AA;
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
DB 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRQRFWRHLVTDIKG 120
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRQRFWRHLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHRYPFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHRYPFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRGRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRGRASEPKHKQ 221
RESULT 8
ID AAB88590
XX AAB88590 standard; protein; 227 AA.
XX
AC AAB88590;
XX
DT 04-JUN-2001 (first entry)
XX
DE Human hydrophobic domain containing protein clone HP03880 #94.
XX
KW Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;
KW antianaemic; vulnary; antiulcer; osteopathic; anti-inflammatory;
KW cytoskeletal; gene therapy; autoimmune disorder; multiple sclerosis;
KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;
KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;
KW behavioural characteristic; immune response.
XX

```

```

OS Homo sapiens.
XX WO200112660-A2.
XX
XX 22-FEB-2001.
XX
XX 10-AUG-2000; 2000WO-JP005356.
XX
XX 17-AUG-1999; 99JP-00230344.
XX 07-SEP-1999; 99JP-00252551.
XX 01-OCT-1999; 99JP-00281132.
XX 22-OCT-1999; 99JP-00301624.
XX 04-NOV-1999; 99JP-00313877.
XX
XX (SAGA ) SAGAMI CHEM RES CENT.
XX (PROT-) PROTEGENE INC.
XX
XX Kato S, Kimura T;
XX
XX WPI; 2001-160059/16.
XX N-PSDB; AAF94480.
XX
XX Human proteins with hydrophobic domains and the DNAs which encode them
XX are useful for treating autoimmune disorders, burns and tumors and for
XX screening novel pharmaceuticals.
XX
XX Claim 1; Page 412-413; 518pp; English.
XX
XX AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
XX AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant,
XX anti-HIV, neuroprotective, antianaemic, vulnary, antiulcer,
XX osteopathic, anti-inflammatory and cytostatic activities, and can be used
XX in gene therapy. (I) can be used as pharmaceuticals and as antigens to
XX prepare antibodies. DNA and cDNA (II) encoding (I) can be used as probes
XX for genetic diagnosis and gene sources for gene therapy or for producing
XX (I) in large quantities. Cells containing (II) are used for the detection
XX of ligands or receptors corresponding to membrane or secretory proteins
XX and to screen small molecule novel pharmaceuticals. Antibodies directed
XX to (I) can be used for the detection, quantification and purification of
XX (I). Activities of (I) may include cytokine and cell
XX proliferation/differentiation function, immune stimulating or suppressing
XX activity, haematopoiesis regulating activity, tissue growth activity,
XX activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, receptor/ligand activity and anti-inflammatory
XX activity. (I) and (II) can be used to treat autoimmune disorders e.g.
XX multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
XX inflammatory bowel disease and tumours. (I) and (II) can also be used for
XX wound healing, as nutritional sources or supplements e.g. as amino acid,
XX carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
XX processing and utilisation of dietary fat, protein, carbohydrate,
XX vitamins and minerals, to effect behavioural characteristics, to affect
XX appetite, and can act as antigens in vaccines to raise an immune response
XX to the protein or another material cross-reactive with the protein
XX
XX Sequence 227 AA;
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
DB 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRQRFWRHLVTDIKG 120
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRQRFWRHLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHRYPFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHRYPFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRGRASEPKHKTR 221

```





CC expression or biological activity, such as coagulation disorders (e.g.  
CC haemophilia), wounds, stroke, thrombosis, myocardial infarction, cancer,  
CC bone fractures, Alzheimer's disease, Parkinson's disease and autoimmune  
CC disorders. The polynucleotides may be used as hybridisation probes, as  
CC oligomers or primers, for polymerase chain reaction, for chromosome and  
CC gene mapping, in the recombinant production of proteins and in generation  
CC of antisense DNA or RNA. The polypeptides may be used in generating  
CC antibodies, as molecular weight markers or as food supplements. This  
CC sequence represents a human polypeptide of the invention.  
XX  
SQ Sequence 183 AA;

Query Match 61.8%; Score 743.5; DB 1; Length 183;  
Best Local Similarity 81.2%; Pred. No. 0;  
Matches 147; Conservative 5; Mismatches 22; Indels 7; Gaps 3;  
QY 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
DB 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHLVTDIKG 120  
DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHLVTDIKG 120  
QY 121 ADLKGKIQGQELSAQAPSPAH--SGFHRVQFFVYLQEGKVISLLPKENKTR----GS 174  
DB 121 ADLKGKIQGQELSAQAPSPAH--SGFHRVQFFVYLQEGKVISLLPKENKTR----GS 174  
QY 175 W 175  
DB 180 W 180

RESULT 13  
RAY11860  
ID AAY11860 standard; protein; 121 AA.  
XX  
AC AAY11860;  
XX  
DT 18-JUN-1999 (first entry)  
XX  
DE Human 5' EST secreted protein SEQ ID No: 460.  
XX  
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;  
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;  
KW upstream regulatory sequence; cytokine activity; cell proliferation;  
KW differentiation; haematopoiesis regulation; tissue growth regulation;  
KW reproductiv hormone regulation; chemotactic; chemokinetic; haemostatic;  
KW thrombolytic; anti-inflammatory; tumour inhibition.  
XX  
OS Homo sapiens.  
XX  
PN WO9906550-A2.  
XX  
PD 11-FEB-1999.  
XX  
PF 31-JUL-1998; 98WO-IB001232.  
XX  
PR 01-AUG-1997; 97US-00905144.  
XX  
PA (GEST ) GENSET.  
XX  
PI Dumas Milne Edwards J, Duclert A, Lacroix B;  
XX  
DR WPI: 1999-153780/13.  
XX  
DR N-PSDB; AAX40582.  
XX  
PT New isolated prostate-derived nucleic acids - used to develop products  
PT which may have cytokine, immune regulatory, haematopoiesis regulating,  
PT anti-inflammatory or tumour inhibition activity.  
XX  
PS Claim 34; Page 589; 675pp; English.  
XX

CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for  
CC human secreted proteins expressed in prostate, and encode the proteins  
CC given in AAY11716 to AAY11993 respectively. The proteins given represent  
CC the signal peptide and an N-terminal fragment of a secreted protein. The  
CC nucleic acid sequences can be used for producing secreted human gene  
CC products. They can also be used to develop products for diagnosis and  
CC therapy. The proteins obtained may have cytokine activity, cell  
CC proliferation and differentiation activity, haematopoiesis regulating  
CC activity, tissue growth regulating activity, reproductiv hormone  
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
CC activity, tumour inhibition activity or other activities. The products  
CC can be used in forensic, gene therapy and chromosome mapping procedures.  
CC The sequences can also be used for obtaining corresponding promoter  
CC sequences. The nucleic acids encoding the signal peptides can be used for  
CC directing extracellular secretion of a polypeptide or the insertion of a  
CC polypeptide into a membrane, or importing a polypeptide into a cell  
XX  
SQ Sequence 121 AA;

Query Match 54.2%; Score 652; DB 1; Length 121;  
Best Local Similarity 99.2%; Pred. No. 0;  
Matches 120; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
DB 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHLVTDIKG 120  
DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHLVTDIKG 120  
QY 121 A 121  
DB 121 A 121

Search completed: February 22, 2005, 12:54:10  
Job time : 0.001 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 14:26:20 ; Search time 0.001 Seconds  
(without alignments)  
521.597 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTWRLVTAALLGLMMVV.....PTLQAPRGRASEPKHKTRQR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 11 seqs, 2339 residues

Word size : 0

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 11 summaries

Database : k035rago.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1196	99.3	223	ADI34902	Cardiovascular dis
2	1181	98.1	227	AAV94263	Human phospholipid
3	1181	98.1	227	ADR88999	Human Phospholipid
4	1181	98.1	227	ADK70502	Respiratory disease
5	1177	97.8	227	AAV35376	Extended human sec
6	1177	97.8	227	AAV64647	Human phosphatidyl
7	1177	97.8	227	AAB88590	Human hydrophobic
8	1173	97.4	227	ADI34900	Cardiovascular dis
9	1067	90.3	201	ADI34903	Cardiovascular dis
10	1064	88.4	205	ADI34901	Cardiovascular dis
11	652	54.2	121	AAV11860	Human 5' EST seque

ALIGNMENTS

RESULT 1  
ADI34902  
ID ADI34902 standard; protein; 223 AA.  
XX  
AC ADI34902;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.  
XX CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;  
KW cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;  
KW cardiovascular disorder; coronary artery disease; human.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers

Peptide 1..22 "signal peptide"  
FT /note= 23..223  
FT Protein /note= "mature protein"  
FT Disulfide-bond 30..58  
FT /note = disulphide bridge  
FT Disulfide-bond 43..64  
FT /note = disulphide bridge  
XX WO2004005931-A1.  
XX 15-JAN-2004.  
XX 26-JUN-2003; 2003WO-EP006766.  
XX 08-JUL-2002; 2002US-0394576P.  
XX 07-JAN-2003; 2003US-0438664P.  
XX (GENE-) GENEPROT INC.  
XX Bougueleret L, Jeandenans C, Pardo B;  
XX WPI; 2004-108914/11.  
XX SWISSPROT; Q8WW74.  
XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful  
XX for useful for screening and/or diagnosis of, or predicting  
XX cardiovascular disorder, or for identifying CPP modulator.  
XX Claim 7; SEQ ID NO 3; 109pp; English.  
XX Thye invention relates to isolated cardiovascular disorder plasma  
XX polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides  
XX derived from them. The CPP fragments are useful for screening and/or  
XX diagnosis of, or predicting a cardiovascular disorder (e.g., coronary  
XX artery disease (CAD)) in a subject. An anti-CPP antibody is useful for  
XX treating cardiovascular disorders e.g., coronary artery disease, stroke,  
XX atherosclerosis, hypertension, etc. The present sequence represents a  
XX human CPP11 precursor protein sequence.  
XX SQ Sequence 223 AA;  
Query Match 99.3%; Score 1196; DB 1; Length 223;  
Best Local Similarity 99.1%; Pred. No. 0;  
Matches 221; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGWTWRLVTAALLGLMMVVTDGDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGWTWRLVTAALLGLMMVVTDGDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPRAEPQRFRHRLVTDING 120  
DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPRAEPQRFRHRLVTDING 120  
QY 121 ADLKGKIQGOELSAQAPSPAHSGFHYOFFVYVLOEGKVISLTPKENKTRGSKWMDRF 180  
DB 121 ADLKGKIQGOELSAQAPSPAHSGFHYOFFVYVLOEGKVISLTPKENKTRGSKWMDRF 180  
QY 181 LNRPHLGEPEASTQFMTQNYODSPTLQAPRGRASEPKHKTRQR 223  
DB 181 LNRPHLGEPEASTQFMTQNYODSPTLQAPRGRASEPKHKTRR 223  
RESULT 2  
AAV94263  
ID AAV94263 standard; protein; 227 AA.  
XX  
AC AAV94263;  
XX  
DT 01-AUG-2000 (first entry)  
XX  
DE Human phospholipid binding protein 2, PLBP2.  
XX



CC endometriosis, polycystic ovary syndrome, cancer, leukaemia, lymphoma,  
 CC AIDS (acquired immunodeficiency syndrome), atherosclerosis and asthma  
 CC (many more examples of these diseases are shown in the specification).  
 CC The present sequence represents human PLBP1.

XX  
 XX Sequence 227 AA;  
 Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDDETLFCQGLEVFYPPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDDETLFCQGLEVFYPPELGNIGCKV 60  
 QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSAEPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSAEPRQRFWRHMLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTQNYQDSPTLQAPGRASEPKHKTR 221  
 Db 181 LNRFLHGEPEASTQFTQNYQDSPTLQAPGRASEPKHKNQ 221

RESULT 4  
 ADK70502  
 ID ADK70502 standard; protein; 227 AA.  
 XX AC ADK70502;  
 XX DT 06-MAY-2004 (first entry)  
 XX DE Respiratory disease differentially expressed protein #68.  
 XX KW cytostatic; respiratory; antiaesthetic; gene therapy;  
 KW differential gene expression; respiratory disorder; lung cancer;  
 KW chronic obstructive pulmonary disease; emphysema; asthma.  
 XX OS Homo sapiens.  
 XX PN WO2003101283-A2.  
 XX PD 11-DEC-2003.  
 XX PF 02-JUN-2003; 2003WO-US017409.  
 XX PR 04-JUN-2002; 2002US-0386005P.  
 XX PA (INCYTE) INCYTE CORP.  
 XX PI Rickert PK, Krasnow R;  
 XX DR WPI; 2004-042945/04.  
 XX PT New combination comprising cDNAs and proteins that are differentially  
 PT expressed in respiratory disorders, useful for diagnosing or treating  
 PT respiratory diseases e.g. lung cancer, chronic obstructive pulmonary  
 PT diseases or asthma.  
 XX PS Claim 14; SEQ ID NO 238; 343pp; English.

CC The invention relates to cDNA sequences that are differentially expressed  
 CC in respiratory disorders or their complements or encoded proteins. The  
 CC cDNAs and proteins are useful for diagnosing, treating or monitoring  
 CC treatment of a subject with a respiratory disease including lung cancer,  
 CC chronic obstructive pulmonary diseases, emphysema or asthma. The protein  
 CC is also useful for screening molecules or compounds to identify at least  
 CC one ligand which specifically binds the protein. It is also useful for  
 CC preparing and purifying a polyclonal or monoclonal antibody. This

CC sequence corresponds to a protein of the invention.

XX  
 XX Sequence 227 AA;  
 Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDDETLFCQGLEVFYPPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDDETLFCQGLEVFYPPELGNIGCKV 60  
 QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSAEPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKFPGAVDGYIILVMVDPDAPSAEPRQRFWRHMLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTQNYQDSPTLQAPGRASEPKHKTR 221  
 Db 181 LNRFLHGEPEASTQFTQNYQDSPTLQAPGRASEPKHKNQ 221

RESULT 5  
 AAY35976  
 ID AAY35976 standard; protein; 227 AA.

XX AC AAY35976;  
 XX DT 13-SEP-1999 (first entry)  
 XX DE Extended human secreted protein sequence, SEQ ID NO. 225.  
 XX KW Secreted protein; human; cytokine; cellular proliferation; cell movement;  
 KW cellular differentiation; immune system regulator; anti-inflammatory;  
 KW haematopoiesis regulator; tissue growth regulator; tumour inhibitor;  
 KW reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;  
 KW genetic disease.  
 XX OS Homo sapiens.  
 XX PN WO9931236-A2.  
 XX PD 24-JUN-1999.  
 XX PF 17-DEC-1998; 98WO-IB002122.  
 XX PR 17-DEC-1997; 97US-0069957P.  
 PR 09-FEB-1998; 98US-0074121P.  
 PR 13-APR-1998; 98US-0081563P.  
 PR 10-AUG-1998; 98US-0096116P.  
 XX PA (GEST) GENSET.  
 XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;  
 XX DR WPI; 1999-385906/32.  
 XX N-PSDB; AAX97660.  
 XX PT New isolated human secreted proteins.  
 XX PS Claim 9; Page 255; 516pp; English.

CC This sequence is encoded by an extended human secreted protein coding  
 CC sequence of the invention. The secreted proteins can be used in treating  
 CC or controlling a variety of human conditions. The secreted proteins may  
 CC act as cytokines or may affect cellular proliferation or differentiation  
 CC or may act as immune system regulators, haematopoiesis regulators, tissue  
 CC growth regulators, regulators of reproductive hormones or cell movement  
 CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or  
 CC tumour inhibition activity. The DNAs can be used in forensic procedures

CC to identify individuals or in diagnostic procedures to identify  
CC individuals having genetic diseases resulting from abnormal expression of  
CC the genes corresponding to the extended cDNAs. They are also useful for  
CC constructing a high resolution map of the human chromosomes. They can  
CC also be used for gene therapy to control or treat genetic diseases  
XX  
SQ Sequence 227 AA;  
  
Query Match 97.8%; Score 1177; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1 MGWTRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
DB 1 MGWTRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
  
QY 61 VPCDNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
DB 61 VPCDNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
  
QY 121 ADLKGKIQOELSAYQAPSPPAHSGFHRYPFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKGKIQOELSAYQAPSPPAHSGFHRYPFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
  
QY 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRASEPKHKTR 221  
DB 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRASEPKHKQ 221  
  
RESULT 6  
AAAY64647  
ID AAY64647 standard; protein; 227 AA.  
AC AAY64647;  
XX  
XX 01-FEB-2000 (first entry)  
XX Human phosphatidylethanolamine-binding protein.  
XX  
XX Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
KW location; development; protein synthesis; stability; regulation;  
KW identification.  
XX  
XX Homo sapiens.  
XX  
XX WO9953051-A2.  
XX  
XX 21-OCT-1999.  
XX 09-APR-1999; 99WO-IB000712.  
XX  
XX 09-APR-1998; 98US-00057719.  
PR 28-APR-1998; 98US-00069047.  
XX  
XX (GEST ) GENSET.  
XX  
XX Dumas Milne Edwards J, Duclert A, Giordano J;  
PI  
XX WPI; 2000-038446/03.  
DR N-PSDB; AAZ42252.  
XX  
XX Novel secreted protein 5', expressed sequence tag sequences used in  
PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.  
XX  
XX Example 21; Page 169-170; 837pp; English.  
XX  
XX AAZ42265 to AAZ43075 represent novel 5' expressed sequence tag (EST)  
CC sequences, corresponding to human secreted proteins. AAAY64651 to AAAY6438  
CC represent the EST-related proteins corresponding to AAZ4265 to AAZ43052.  
CC The 5' ESTs can be used for producing secreted human gene products. They  
CC can be used to identify and isolate 5' untranslated regions (UTRs) and  
CC upstream regulatory regions which control the location, development

CC stage, rate, and quantity of protein synthesis, as well as stability of  
CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to  
CC obtain full length cDNA clones. The ESTs can also be used in forensic  
CC procedures to identify individuals, or in diagnostic procedures to  
CC identify individuals having genetic diseases resulting from abnormal gene  
CC expression. The products may also be used in gene therapy protocols. The  
CC nucleic acids encoding signal peptides can be used for directing  
CC extracellular secretion of a polypeptide or the insertion of a  
CC polypeptide into a membrane, or importing a polypeptide into a cell. The  
CC proteins encoded by the EST sequences may be useful in treating a variety  
CC of human conditions. Secreted proteins have therapeutic value, and the  
CC identification of new secreted proteins is valuable. AAZ42249 to AAZ42264  
CC and AAAY64644 to AAAY64650 represent sequences used in the exemplification  
CC of the present invention  
XX  
SQ Sequence 227 AA;  
  
Query Match 97.8%; Score 1177; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1 MGWTRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
DB 1 MGWTRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60  
  
QY 61 VPCDNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
DB 61 VPCDNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
  
QY 121 ADLKGKIQOELSAYQAPSPPAHSGFHRYPFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKGKIQOELSAYQAPSPPAHSGFHRYPFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
  
QY 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRASEPKHKTR 221  
DB 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRASEPKHKQ 221  
  
RESULT 7  
AAB88590  
ID AAB88590 standard; protein; 227 AA.  
AC AAB88590;  
XX  
XX 04-JUN-2001 (first entry)  
XX Human hydrophobic domain containing protein clone HP03880 #94.  
XX  
XX Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;  
KW antianemic; vulnery; antiulcer; osteopathic; anti-inflammatory;  
KW cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;  
KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;  
KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;  
KW behavioural characteristic; immune response.  
XX  
XX Homo sapiens.  
XX  
XX WO200112660-A2.  
XX  
XX 22-FEB-2001.  
XX  
XX 10-AUG-2000; 2000WO-JP0053356.  
XX  
XX 17-AUG-1999; 99JP-00210344.  
PR 07-SEP-1999; 99JP-00252551.  
PR 01-OCT-1999; 99JP-00281132.  
PR 22-OCT-1999; 99JP-00301624.  
PR 04-NOV-1999; 99JP-00313877.  
XX  
XX (SAGA ) SAGAMI CHEM RES CENT.  
PA (PROT-) PROTEGENE INC.  
XX  
XX Kato S, Kimura T; PI



```

XX WPI: 2001-160059/16.
DR N-PSDB; AAF94480.
XX
PT Human proteins with hydrophobic domains and the DNAs which encode them
PT are useful for treating autoimmune disorders, burns and tumors and for
PT screening novel pharmaceuticals.
XX
XX Claim 1; Page 412-413; 518pp; English.
XX
PS AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
CC AAB88606 (I) which have a hydrophobic domain. (II) have immunosuppressant,
CC anti-HIV, neuroprotective, antianaemic, vulnerary, antitumor,
CC osteopathic, anti-inflammatory and cytostatic activities, and can be used
CC to prepare antibodies. DNA and cDNA (II) encoding (I) can be used as probes
CC for genetic diagnosis and gene sources for gene therapy or for producing
CC (I) in large quantities. Cells containing (I) are used for the detection
CC of ligands or receptors corresponding to membrane or secretory proteins
CC and to screen small molecule novel pharmaceuticals. Antibodies directed
CC to (I) can be used for the detection, quantification and purification of
CC (II). Activities of (I) may include cytokine and cell
CC proliferation/differentiation function, immune stimulating or suppressing
CC activity, haematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, receptor/ligand activity and anti-inflammatory
CC activity. (I) and (II) can be used to treat autoimmune disorders e.g.
CC multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
CC inflammatory bowel disease and tumours. (I) and (II) can also be used for
CC wound healing, as nutritional sources or supplements e.g. as amino acid,
CC carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
CC processing and utilisation of dietary fat, protein, carbohydrate,
CC vitamins and minerals, to effect behavioural characteristics, to affect
CC appetite, and can act as antigens in vaccines to raise an immune response
CC to the protein or another material cross-reactive with the protein
XX
SQ Sequence 227 AA;

Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 MGWTMLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGWTMLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60

QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
DB 61 VPCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120

QY 121 ADLKGKIQGOELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGOELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180

QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLOAPRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLOAPRASEPKHKQ 221

RESULT 8
ADI34900
ID ADI34900 standard; protein; 227 AA.
XX
XX ADI34900;
XX
XX 06-MAY-2004 (first entry)
XX
DE Cardiovascular disorder plasma polypeptide (CPP) 10 precursor sequence.
XX
XX CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
KW cardiac; cerebroprotective; antiarteriosclerotic; hypotensive;
KW cardiovascular disorder; coronary artery disease; human.
XX

```

---

```

OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..22
FT Protein /note= "signal peptide"
FT Protein 23..227
FT Disulfide-bond 30..58
FT Disulfide-bond /note= "mature protein"
FT Disulfide-bond 43..64
FT Disulfide-bond /note= "disulphide bridge"
FT Disulfide-bond /note= "disulphide bridge"
XX
XX WO2004005931-A1.
XX
XX 15-JAN-2004.
XX
XX 26-JUN-2003; 2003WO-EP006766.
XX
XX 08-JUL-2002; 2002US-0394576P.
XX
XX 07-JAN-2003; 2003US-0438664P.
XX
XX (GENE-) GENEPROT INC.
XX
XX Bougueleret L, Jeandenans C, Pardo B;
XX
XX WPI: 2004-108914/11.
XX
XX SWISSPROT; Q96S96.
XX
XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
XX for useful for screening and/or diagnosis of, or predicting
XX cardiovascular disorder, or for identifying CPP modulator.
XX
XX Claim 7; SEQ ID NO 1; 109pp; English.
XX
XX Thye invention relates to isolated cardiovascular disorder plasma
XX polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
XX derived from them. The CPP fragments are useful for screening and/or
XX diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
XX artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
XX treating cardiovascular disorders e.g., coronary artery disease, stroke,
XX atherosclerosis, hypertension, etc. The present sequence represents a
XX human CPP10 precursor protein sequence.
XX
XX Sequence 227 AA;

Query Match 97.4%; Score 1173; DB 1; Length 227;
Best Local Similarity 98.2%; Pred. No. 0;
Matches 217; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 MGWTMLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGWTMLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60

QY 61 VPCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
DB 61 VPCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120

QY 121 ADLKGKIQGOELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGOELSAQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180

QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLOAPRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLOAPRASEPKHKQ 221

RESULT 9
ADI34903
ID ADI34903 standard; protein; 201 AA.
XX
XX ADI34903;
XX
XX 06-MAY-2004 (first entry)
XX

```

XX	06-MAY-2004	(first entry)
XX	Cardiovascular disorder plasma polypeptide (CPP) 10 mature protein.	
XX	Cardiovascular disorder plasma polypeptide (CPP) 10 mature protein.	
XX	CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;	
XX	cardiac; cerebroprotective; antiarteriosclerotic; hypotensive;	
KW	cardiovascular disorder; coronary artery disease; human.	
KW	cardiovascular disorder; coronary artery disease; human.	
XX	Homo sapiens.	
OS		
XX	Key Location/Qualifiers	
FH	Disulfide-bond 8..36	
FT	/note = disulphide bridge	
FT	Disulfide-bond 21..42	
FT	/note = disulphide bridge	
XX		
XX	WO2004005931-A1.	
PN		
XX	15-JAN-2004.	
PD		
XX	26-JUN-2003; 2003WO-EPO06766.	
PF		
XX	08-JUL-2002; 2002US-0394576P.	
PR		
XX	07-JAN-2003; 2003US-0438664P.	
PR		
XX	(GENE-) GENEPROT INC.	
PA		
XX	Bougueleret L, Jeandenans C, Pardo B;	
PI		
XX	WPI; 2004-108914/11.	
DR		
XX	Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful	
XX	for useful for screening and/or diagnosis of, or predicting	
PT	cardiovascular disorder, or for identifying CPP modulator.	
PT		
XX	Claim 7; SEQ ID NO 2; 109pp; English.	
PS		
XX	This invention relates to isolated cardiovascular disorder plasma	
CC	polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides	
CC	derived from them. The CPP fragments are useful for screening and/or	
CC	diagnosis of, or predicting a cardiovascular disorder (e.g., coronary	
CC	artery disease (CAD)) in a subject. An anti-CPP antibody is useful for	
CC	treatment of cardiovascular disorders e.g., coronary artery disease, stroke,	
CC	atherosclerosis, hypertension, etc. The present sequence represents a	
CC	human CPP10 mature protein sequence.	
XX		
SQ	Sequence 205 AA;	
Query Match 88.4%; Score 1064; DB 1; Length 205;		
Best Local Similarity 98.0%; Pred. No. 0;		
Matches 195; Conservative 2; Mismatches 2; Indels 0; Gaps 0		
OY	23 DEDENSPCAHFALLDDETLFCOGLEVFPELGNIGCKVVPDCNNYRKITSWMEPIVKFP 82	
Db	1 DEDENSPCAHFALLDDETLFCOGLEVFPELGNIGCKVVPDCNNYRKITSWMEPIVKFP 60	
OY	83 GAVDGATVILVMVDPDAPSRAPRQRFRWHVLVTDIKGADLKKGKIQOGLSAYQASP 142	
Db	61 GAVDGATVILVMVDPDAPSRAPRQRFRWHVLVTDIKGADLKKGKIQOGLSAYQASP 120	
OY	143 AHSGFHRVQFFYYLOEGKVISLLPKENTRGSKWMDFLNPHFLGEPEASTQFMNTQYD 202	
Db	121 AHSGFHRYQFFYYLOEGKVISLLPKENTRGSKWMDFLNPHFLGEPEASTQFMNTQYD 180	
OY	203 SPTLQAPRASPEPKHKTR 221	
Db	181 SPTLQAPRASPEPKHKQ 199	
RESULT 11		
AAy11860		
ID AAY11860 standard; protein; 121 AA.		

Search completed: February 22, 2005, 14:26:21  
Job time : 1 secs

```

XX AAY11860;
AC
XX 18-JUN-1999 (first entry)
DT
XX
DE Human 5' EST secreted protein SEQ ID No: 460.
XX
XX Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
XX WO9906550-A2.
FN
XX
XX PD
PD
XX
XX 31-JUL-1998; 98WO-IB001232.
PF
XX
XX 01-AUG-1997; 97US-00905144.
PR
XX
XX (GEST ) GENSET.
PA
XX
XX Dumas Milne Edwards J, Duclert A, Lacroix B;
PI
XX
XX WPI; 1999-153780/13.
DR
XX N-PSDB; AAX40582.
XX
XX New isolated prostate-derived nucleic acids - used to develop products
PT which may have cytokine, immune regulatory, haematopoiesis regulating,
PT anti-inflammatory or tumour inhibition activity.
XX
XX Claim 34; Page 589; 675pp; English.
PS
XX
XX AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductiv hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell
XX
XX Sequence 121 AA;
SQ
Query Match 54.2%; Score 652; DB 1; Length 121;
Best Local Similarity 99.2%; Pred. No. 0;
Matches 120; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MCGWTRLVTAAALLGLMMVVTGDEDNPSCAHEALLDEDTLFCQGLEVPYPBELGNIGCKV 60
DB 1 MCGWTRLVTAAALLGLMMVVTGDEDNPSCAHEALLDEDTLFCQGLEVPYPBELGNIGCKV 60

QY 61 VPDCCNYROKITSWNEPIVKPFCAVDGATYILVMVDPDAPSRAEPRQRFWRHLVTDIKG 120
DB 61 VPDCCNYROKITSWNEPIVKPFCAVDGATYILVMVDPDAPSRAEPRQRFWRHLVTDIKG 120

QY 121 A 121
DB 121 A 121

```

